BIOS Fund II, LP's Form 4 filing
IN8BIO, Inc. (INAB) · filed Aug 30, 2022
- Accession no.
- 0001104659-22-095839
- Filed
- Aug 30, 2022, 8:10 AM ET
- Trade date
- Aug 26-29, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market purchases total $103.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BIOS Fund II, LPCIK 0001714576 | Director, 10% Owner |
| BIOS Fund II QP, LPCIK 0001716869 | Director, 10% Owner |
| BIOS Fund II NT, LPCIK 0001728851 | Director, 10% Owner |
| BIOS Incysus Co-Invest I, LPCIK 0001740029 | Director, 10% Owner |
| Cavu Management, LPCIK 0001813270 | Director, 10% Owner |
| Cavu Advisors, LLCCIK 0001813310 | Director, 10% Owner |
| Bios Equity Partners II, LPCIK 0001813313 | Director, 10% Owner |
| Kreis Leslie W.CIK 0001813316 | Director, 10% Owner |
| BIOS Equity Partners III, LPCIK 0001831976 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2022 | Common Stock | PPurchaseAcquired | +1,377 | $2.01F12 | +$2,767.77 | 584,784 | Indirect | |
| Aug 29, 2022 | Common Stock | PPurchaseAcquired | +4,912 | $2.02F12 | +$9,922.24 | 589,696 | Indirect | |
| Aug 26, 2022 | Common Stock | PPurchaseAcquired | +8,531 | $2.01F12 | +$17,147.31 | 3,621,100 | Indirect | |
| Aug 29, 2022 | Common Stock | PPurchaseAcquired | +30,428 | $2.02F12 | +$61,464.56 | 3,651,528 | Indirect | |
| Aug 26, 2022 | Common Stock | PPurchaseAcquired | +1,306 | $2.01F12 | +$2,625.06 | 554,416 | Indirect | |
| Aug 29, 2022 | Common Stock | PPurchaseAcquired | +4,660 | $2.02F12 | +$9,413.2 | 559,076 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F12
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4.
Referenced by the price of 6 transactions in Table I.
Remarks
This Form 4 is the first of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The second Form 4 will be filed by Aaron G.L. Fletcher as the designated filer.